Imvanex is a vaccine used to protect against smallpox in adults and adolescents aged 12 years and older. Smallpox was officially declared eradicated in 1980, with the last known case of the disease occurring in 1977. This vaccine will be used when it is considered necessary to protect against smallpox in accordance with official recommendations. Imvanex can also be used to protect adults and adolescents aged 12 years and older from mpox (formerly monkeypox) and disease caused by the vaccinia virus. Imvanex contains an attenuated (weakened) form of the vaccinia virus called ‘modified vaccinia virus Ankara’, which is related to the smallpox and mpox viruses.
Therapeutic Indication
### Therapeutic indication Active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in individuals 12 years of age and older (see sections 4.4 and 5.1). The use of this vaccine should be in accordance with official recommendations.
Therapeutic Area (MeSH)
ATC Code
J07BX
ATC Item
其它病毒疫苗
Pharmacotherapeutic Group
Other viral vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus | N/A | modified vaccinia ankara - bavarian nordic (mva-bn) virus |
EMA Name
Imvanex
Medicine Name
Imvanex
Aliases
N/ANo risk management plan link.
